By Spondylitis Association of America
Biologic medications, such as TNF inhibitors (TNFi) and IL-17 inhibitors (IL-17i), are the current standard in rheumatologic treatment of moderate to severe spondyloarthritis. But what happens when patients don’t respond to this class of medications?
The following is an announcement from SAA about a third party clinical trial. SAA is not affiliated with this study, the researchers, or the drug manufacturer.
AbbVie is giving away 45 college scholarships of $15,000 each to U.S. residents living with inflammatory diseases.
Esteemed rheumatologist and researcher, Atul Deodhar, M.D., M.R.C.P. discusses his new axial spondyloarthritis study, which concludes in supporting TNF inhibitor use in nonradiographic axial spondyloarthritis.
What you can do if you are suffering but don’t have health insurance and can’t afford to see a doctor or get treatment.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.